濵田医師の論文がERJ Open Researchでアクセプトされました。

最近の投稿

• Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
• 育成賞を受賞しました！
• Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study
• eClinical Medicine. 2024 Mar 22:70:102536. doi:10.1016/j.eclinm.2024.102536Title : Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective
• First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462.